Efficacy analysis of tiotropium bromide inhalant in the treatment of COPD in stable period D group

ObjectiveTo investigate the effects of tiotropium bromide inhalant on clinical symptoms, pulmonary function and quality of life in patients with chronic obstructive pulmonary disease(COPD) in stable group D.

MethodsNinety-two patients with stable COPD in group D(according to GOLD 2018) were randomly divided into the observation group(n=46) and control group(n=46).The control group was treated with function exercise and budesonide/formoterol inhalation, and the observation group was treated with tiotropium bromide inhalant on the basis of the control group.After six months of treatment, the lung function(FEV1 and FVC), six-minute walking distance(6MWD), clinical symptom score(CAT), dyspnea degree(mMRC score), quality of life(SGRQ score) were compared between two groups.

ResultsAfter treatment, the FEV1 and FVC in two groups were improved compared with those before treatment, and the FEV1 and FVC in observation group were higher than those in control group(P < 0.01).After treatment, the 6MWD in two groups was improved compared with that before treatment, and the 6MWD in observation group was higher than that in control group(P < 0.01).After treatment, the scores of the CAT, mMRC and SGRQ reduced, and the improvement degree in observation group was better than that in control group(P < 0.01).

ConclusionsTiotropium bromide inhalant combined with pulmonary function exercise and budesonide/formoterol in treating the stable COPD in group D can effectively improve the symptoms, pulmonary function and quality of life of patients.